Abstract:Duchenne muscular dystrophy (DMD) is a currently incurable X-linked neuromuscular disorder, characterized by progressive muscle wasting and premature death, typically as a consequence of cardiac failure. DMD-causing mutations in the dystrophin gene are highly diverse, meaning that the development of a universally-applicable therapy to treat all patients is very challenging. The leading therapeutic strategy for DMD is antisense oligonucleotide-mediated splice modulation, whereby one or more specific exons are excluded from the mature dystrophin mRNA in order to correct the translation reading frame. Indeed, three exon skipping oligonucleotides have received FDA approval for use in DMD patients. Second-generation exon skipping drugs (i.e. peptide-antisense oligonucleotide conjugates) exhibit enhanced potency, and also induce dystrophin restoration in the heart. Similarly, multiple additional antisense oligonucleotide drugs targeting various exons are in clinical development in order to treat a greater proportion of DMD patient mutations. Relatively recent advances in the field of genome engineering (specifically, the development of the CRISPR/Cas system) have provided multiple promising therapeutic approaches for the RNA-directed genetic correction of DMD, including exon excision, exon reframing via the introduction of insertion/deletion mutations, disruption of splice signals to promote exon skipping, and the templated correction of point mutations by seamless homology directed repair or base editing technology. Potential limitations to the clinical translation of the splice modulation and gene editing approaches are discussed, including drug delivery, the importance of uniform dystrophin expression in corrected myofibres, safety issues (e.g. renal toxicity, viral vector immunogenicity, and off-target gene editing), and the high cost of therapy.

Correction of a Splicing Defect in a Mouse Model of Congenital Muscular Dystrophy Type 1A Using a Homology-Directed-repair-independent Mechanism.

Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing

A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing

Single-Swap Editing for the Correction of Common Duchenne Muscular Dystrophy Mutations

Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing

Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy

In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers

In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse

Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model

A Consolidated AAV System for Single-Cut CRISPR Correction of a Common Duchenne Muscular Dystrophy Mutation

CRISPR-Cas9 Corrects Duchenne Muscular Dystrophy Exon 44 Deletion Mutations in Mice and Human Cells.

Efficient correction of Duchenne muscular dystrophy mutations by SpCas9 and dual gRNAs

Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing

In vivo gene editing in dystrophic mouse muscle and muscle stem cells

Long-term Maintenance of Dystrophin Expression and Resistance to Injury of Skeletal Muscle in Gene Edited DMD Mice.

Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy

Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1

CRISPR-Cas9 correction in the DMD mouse model is accompanied by upregulation of Dp71f protein

Toward the correction of muscular dystrophy by gene editing

Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system

In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy